These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23486237)

  • 1. Time-dependent resistance to erythropoiesis-stimulating agent and mortality in hemodialysis patients in the Japan Dialysis Outcomes and Practice Patterns Study.
    Fujikawa T; Ikeda Y; Fukuhara S; Akiba T; Akizawa T; Kurokawa K; Saito A
    Nephron Clin Pract; 2012; 122(1-2):24-32. PubMed ID: 23486237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients.
    Rivara MB; Ikizler TA; Ellis CD; Mehrotra R; Himmelfarb J
    BMC Nephrol; 2015 Jun; 16():79. PubMed ID: 26045064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan.
    Fukuma S; Yamaguchi T; Hashimoto S; Nakai S; Iseki K; Tsubakihara Y; Fukuhara S
    Am J Kidney Dis; 2012 Jan; 59(1):108-16. PubMed ID: 21890255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-reactive protein but not hepcidin, NGAL and transferrin determines the ESA resistance in hemodialysis patients.
    Yılmaz I; Ozkok A; Kostek O; Kolukısa A; Duran I; Odabaş AR; Kemal Işman F; Işbilen Başok B
    Ren Fail; 2016; 38(1):89-95. PubMed ID: 26539647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.
    Ogawa T; Shimizu H; Kyono A; Sato M; Yamashita T; Otsuka K; Nitta K
    Int Urol Nephrol; 2014 Jan; 46(1):151-9. PubMed ID: 23807369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Butyrylcholinesterase level as an independent factor of erythropoiesis-stimulating agent resistance in patients on maintenance hemodialysis: a single-center cross-sectional study.
    Okamoto T; Hatakeyama S; Tanaka Y; Imanishi K; Takashima T; Saitoh F; Koie T; Suzuki T; Ohyama C
    Clin Exp Nephrol; 2018 Oct; 22(5):1174-1181. PubMed ID: 29600410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyporesponsiveness to erythropoiesis-stimulating agent as a prognostic factor in Japanese hemodialysis patients: the Q-Cohort study.
    Eriguchi R; Taniguchi M; Ninomiya T; Hirakata H; Fujimi S; Tsuruya K; Kitazono T
    J Nephrol; 2015 Apr; 28(2):217-25. PubMed ID: 25080399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships among the Dosage of Erythropoiesis-Stimulating Agents, Erythropoietin Resistance Index, and Mortality in Maintenance Hemodialysis Patients.
    Pan S; Zhao DL; Li P; Sun XF; Zhou JH; Song KK; Wang Y; Miao LN; Ni ZH; Lin HL; Liu FY; Li Y; He YN; Wang NS; Wang CL; Zhang AH; Chen MH; Yang XP; Deng YY; Shao FM; Fu SX; Fang JA; Cai GY; Chen XM
    Blood Purif; 2022; 51(2):171-181. PubMed ID: 34175850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study.
    Panichi V; Scatena A; Rosati A; Giusti R; Ferro G; Malagnino E; Capitanini A; Piluso A; Conti P; Bernabini G; Migliori M; Caiani D; Tetta C; Casani A; Betti G; Pizzarelli F
    Nephrol Dial Transplant; 2015 Apr; 30(4):682-9. PubMed ID: 25385719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evolution of the darbepoetin alpha resistance index in patients on dialysis who change from weekly to fortnightly treatments in clinical practice].
    López-Gómez JM; de Francisco AL; Montenegro J; de Santiago C; Vera M; Donapetry C; Villaverde M
    Nefrologia; 2010; 30(1):64-72. PubMed ID: 20098471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
    Bae MN; Kim SH; Kim YO; Jin DC; Song HC; Choi EJ; Kim YL; Kim YS; Kang SW; Kim NH; Yang CW; Kim YK
    PLoS One; 2015; 10(11):e0143348. PubMed ID: 26588085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients.
    Okazaki M; Komatsu M; Kawaguchi H; Tsuchiya K; Nitta K
    Blood Purif; 2014; 37(2):106-12. PubMed ID: 24603656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to Erythropoiesis-Stimulating Agents in Pre-Dialysis and Post-Dialysis Mortality in Japanese Incident Hemodialysis Patients.
    Hayashi T; Joki N; Tanaka Y; Iwasaki M; Kubo S; Matsukane A; Takahashi Y; Imamura Y; Hirahata K; Hase H
    Blood Purif; 2019; 47 Suppl 2(Suppl 1):31-37. PubMed ID: 30943479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Not baseline but time-dependent erythropoiesis-stimulating agent responsiveness predicts cardiovascular disease in hemodialysis patients receiving epoetin beta pegol: A multicenter prospective PARAMOUNT-HD Study.
    Fujii H; Hamano T; Tsuchiya K; Kuragano T; Joki N; Tsuruya K; Honda H; Uemura Y; Nitta K;
    Int J Cardiol; 2023 Mar; 375():110-118. PubMed ID: 36592827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient.
    Goodkin DA; Zhao J; Cases A; Nangaku M; Karaboyas A
    Am J Nephrol; 2022; 53(5):333-342. PubMed ID: 35462377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between red cell distribution width with erythropoietin resistance in iron replete hemodialysis patients.
    Afsar B; Saglam M; Yuceturk C; Agca E
    Eur J Intern Med; 2013 Apr; 24(3):e25-9. PubMed ID: 23246125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients.
    Petrulienė K; Žiginskienė E; Kuzminskis V; Nedzelskienė I; Bumblytė IA
    Medicina (Kaunas); 2017; 53(2):90-100. PubMed ID: 28416170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study.
    Panichi V; Rosati A; Bigazzi R; Paoletti S; Mantuano E; Beati S; Marchetti V; Bernabini G; Grazi G; Rizza GM; Migliori M; Giusti R; Lippi A; Casani A; Barsotti G; Tetta C;
    Nephrol Dial Transplant; 2011 Aug; 26(8):2641-8. PubMed ID: 21325348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of the erythropoiesis-stimulating agent resistance index and the geriatric nutritional risk index with cardiovascular mortality in maintenance hemodialysis patients.
    Yajima T; Yajima K; Takahashi H
    PLoS One; 2021; 16(1):e0245625. PubMed ID: 33449974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.